Antiâ€“spike IgG causes severe acute lung injury by ske acute SARS-CoV infection

JCI Insight

4,

DOI: 10.1172/jci.insight.123158

Citation Report

#	Article	IF	Citations
1	Severe Acute Respiratory Syndrome. Infectious Disease Clinics of North America, 2019, 33, 869-889.	1.9	424
2	Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. Frontiers in Immunology, 2020, 11, 561851.	2.2	4
3	Immunotherapeutic approaches to curtail COVID-19. International Immunopharmacology, 2020, 88, 106924.	1.7	57
4	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine, 2020, 38, 7533-7541.	1.7	84
5	ChAdOx1ÂnCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578-582.	13.7	840
6	COVID-19 Vaccines: Should We Fear ADE?. Journal of Infectious Diseases, 2020, 222, 1946-1950.	1.9	55
7	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12, .	5.8	204
8	Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?. Frontiers in Immunology, 2020, 11, 567710.	2.2	49
9	Divergent SARSâ€CoVâ€2â€specific Tâ€and Bâ€cell responses in severe but not mild COVIDâ€19 patients. European Journal of Immunology, 2020, 50, 1998-2012.	1.6	116
10	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell, 2020, 183, 169-184.e13.	13.5	446
11	On the genetics and immunopathogenesis of COVID-19. Clinical Immunology, 2020, 220, 108591.	1.4	32
12	Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell responseâœ°,âœ°âœ°. EBioMedicine, 2020, 60, 103008.	2.7	6
13	Severe COVID-19: what have we learned with the immunopathogenesis?. Advances in Rheumatology, 2020, 60, 50.	0.8	53
14	Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19. Journal of Immunology, 2020, 205, 2719-2725.	0.4	21
15	What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. Vaccine: X, 2020, 6, 100076.	0.9	62
16	COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis. Frontiers in Immunology, 2020, 11, 2086.	2.2	12
17	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. Frontiers in Pharmacology, 2020, 11, 1224.	1.6	30
18	Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment. Frontiers in Immunology, 2020, 11, 570063.	2.2	13

#	Article	IF	Citations
19	As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention. Frontiers in Immunology, 2020, 11, 591897.	2.2	14
20	Rabies virus-based COVID-19 vaccine CORAVAXâ„¢ induces high levels of neutralizing antibodies against SARS-CoV-2. Npj Vaccines, 2020, 5, 98.	2.9	26
22	Immunology of COVIDâ€19 and diseaseâ€modifying therapies: the good, the bad and the unknown. European Journal of Neurology, 2020, 28, 3503-3516.	1.7	20
23	Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19. Medical Hypotheses, 2020, 144, 110043.	0.8	13
24	Successful transfer of antiâ€“SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Advances, 2020, 4, 4864-4868.	2.5	20
25	A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 2020, 5, 237.	7.1	427
26	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, The, 2020, 396, 1595-1606.	6.3	511
27	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 2020, 225, 152008.	0.8	65
28	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in Immunology, 2020, 41, 1100-1115.	2.9	794
29	Update on serologic testing in COVIDâ€“19. Clinica Chimica Acta, 2020, 510, 746-750.	0.5	29
30	Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine, 2020, 38, 7205-7212.	1.7	31
31	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research, 2020, 288, 198141.	1.1	116
32	Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine. ACS Central Science, 2020, 6, 1341-1347.	5.3	11
33	Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. Critical Care, 2020, 24, 449.	2.5	16
34	Immune-mediated approaches against COVID-19. Nature Nanotechnology, 2020, 15, 630-645.	15.6	260
35	The role of host genetics in the immune response to SARSâ€CoVâ€2 and COVIDâ€19 susceptibility and severity. Immunological Reviews, 2020, 296, 205-219.	2.8	175
36	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. Life Sciences, 2020, 257, 118058.	2.0	11
37	Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity, 2020, 53, 248-263.	6.6	281

#	Article	IF	Citations
38	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Frontiers in Immunology, 2020, 11, 1660.	2.2	48
39	Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Life Sciences, 2020, 257, 118102.	2.0	248
40	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
41	Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development. Journal of Translational Medicine, 2020, 18, 281.	1.8	32
42	Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nature Communications, 2020, 11, 5752.	5.8	59
43	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nature Communications, 2020, 11, 5838.	5.8	225
44	Acute Kidney Injury in Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus-2 Pandemic: Experience From PICUs Across United Kingdom*. Critical Care Medicine, 2020, 48, 1809-1818.	0.4	33
45	Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Immunity, 2020, 53, 1315-1330.e9.	6.6	215
46	Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. Emerging Microbes and Infections, 2020, 9, 2606-2618.	3.0	28
47	Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. Microorganisms, 2020, 8, 1840.	1.6	14
48	Recommendations for the Diagnosis, Prevention, and Control of Coronavirus Disease-19 in Childrenâ€"The Chinese Perspectives. Frontiers in Pediatrics, 2020, 8, 553394.	0.9	26
49	Serodiagnostics for Severe Acute Respiratory Syndromeâ€"Related Coronavirus 2. Annals of Internal Medicine, 2020, 173, 450-460.	2.0	124
50	A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32657-32666.	3.3	60
51	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Frontiers in Microbiology, 2020, 11, 588409.	1.5	19
52	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). Journal of Cardiac Critical Care TSS, 2020, 4, 121-131.	0.0	0
53	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. Microorganisms, 2020, 8, 1733.	1.6	16
54	I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. Frontiers in Immunology, 2020, 11, 579220.	2.2	115
55	Dysregulated adaptive immune response contributes to severe COVID-19. Cell Research, 2020, 30, 814-816.	5.7	71

#	Article	IF	Citations
56	COVIDâ€19 and immunological regulations â€“ from basic and translational aspects to clinical implications. JDDG - Journal of the German Society of Dermatology, 2020, 18, 795-807.	0.4	45
57	Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity, 2020, 53, 864-877.e5.	6.6	450
58	Blood Banking and Transfusion Medicine Challenges During the COVID-19 Pandemic. Clinics in Laboratory Medicine, 2020, 40, 587-601.	0.7	72
59	Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Multiple Sclerosis Journal, 2020, 26, 1261-1264.	1.4	33
60	Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review . Infection and Drug Resistance, 2020, Volume 13, 2657-2665.	1.1	70
61	The role of IgG Fc receptors in antibody-dependent enhancement. Nature Reviews Immunology, 2020, 20, 633-643.	10.6	340
62	Promise and challenges in the development of COVID-19 vaccines. Human Vaccines and Immunotherapeutics, 2020, 16, 2604-2608.	1.4	31
63	From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry. Antibodies, 2020, 9, 33.	1.2	79
64	Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy . Infection and Drug Resistance, 2020, Volume 13, 2485-2493.	1.1	93
65	A Thermostable mRNA Vaccine against COVID-19. Cell, 2020, 182, 1271-1283.e16.	13.5	485
66	COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Human Vaccines and Immunotherapeutics, 2020, 16, 2891-2904.	1.4	53
67	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	2.7	120
68	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584, 120-124.	13.7	1,237
69	Immunometabolic Status of COVID-19 Cancer Patients. Physiological Reviews, 2020, 100, 1839-1850.	13.1	20
70	Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Frontiers in Molecular Biosciences, 2020, 7, 157.	1.6	407
71	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine, 2020, 58, 102887.	2.7	114
72	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Trends in Pharmacological Sciences, 2020, 41, 815-829.	4.0	108
73	Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. Frontiers in Pharmacology, 2020, 11, 1169.	1.6	108

#	Article	IF	Citations
74	SARS-CoV-2-specific ELISA development. Journal of Immunological Methods, 2020, 484-485, 112832.	0.6	77
75	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. Cellular and Molecular Bioengineering, 2020, 13, 259-284.	1.0	5
76	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. Frontiers in Cellular and Infection Microbiology, 2020, 10, 575404.	1.8	4
77	Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. Frontiers in Immunology, 2020, 11, 596761.	2.2	45
78	Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. Journal of Translational Medicine, 2020, 18, 406.	1.8	123
79	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. International Journal of Antimicrobial Agents, 2020, 56, 106208.	1.1	22
80	Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. Journal of Experimental Medicine, 2020, 217, .	4.2	55
81	What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist. Frontiers in Immunology, 2020, 11, 2173.	2.2	8
82	Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19. Human Vaccines and Immunotherapeutics, 2020, 16, 2973-2979.	1.4	5
83	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduction and Targeted Therapy, 2020, 5, 180.	7.1	222
84	Convalescent plasma treatment for COVIDâ€19: Tempering expectations with the influenza experience. European Journal of Immunology, 2020, 50, 1447-1453.	1.6	14
85	Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 2020, 20, 615-632.	10.6	806
86	Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine, 2020, 12, .	5.8	298
87	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and â€œNew Old Friendsâ€• Frontiers in Immunology, 2020, 11, 2059.	2.2	18
89	Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes and Infection, 2020, 22, 515-524.	1.0	23
90	Antibody-dependent enhancement of coronavirus. International Journal of Infectious Diseases, 2020, 100, 483-489.	1.5	77
91	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25018-25025.	3.3	279
92	Vaccination against SARS-CoV-2 and disease enhancement â€“ knowns and unknowns. Expert Review of Vaccines, 2020, 19, 691-698.	2.0	19

#	Article	IF	Citations
94	CT Findings in a Novel Coronavirus Disease (COVID-19) Pneumonia at Initial Presentation. BioMed Research International, 2020, 2020, 1-10.	0.9	10
95	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	2.1	103
96	Monocyte activation in systemic Covid-19 infection: Assay and rationale. EBioMedicine, 2020, 59, 102964.	2.7	80
97	Antibody Response to Severe Acute Respiratory Syndromeâ€•Corona Virus 2, Diagnostic and Therapeutic Implications. Hepatology Communications, 2020, 4, 1731-1743.	2.0	6
98	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2020, 16, 2921-2931.	1.4	85
99	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Frontiers in Medical Technology, 2020, 2, 571030.	1.3	29
100	Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?. Pathogens, 2020, 9, 739.	1.2	7
101	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	1.1	185
102	Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients at Risk?. Pharmaceuticals, 2020, 13, 238.	1.7	9
103	The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector. Molecular Biology, 2020, 54, 812-826.	0.4	23
104	How to Survive COVIDâ€19 Even If the Vaccine Fails. Hepatology Communications, 2020, 4, 1864-1879.	2.0	1
105	The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. Frontiers in Immunology, 2020, 11, 2033.	2.2	69
106	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology, 2020, 5, 1185-1191.	5.9	553
107	Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability. Clinical Infectious Diseases, 2021, 73, e550-e558.	2.9	14
108	Coronavirus disease 2019 (COVID-19) in domestic animals and wildlife: advances and prospects in the development of animal models for vaccine and therapeutic research. Human Vaccines and Immunotherapeutics, 2020, 16, 3043-3054.	1.4	26
109	A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathogens, 2020, 16, e1008796.	2.1	90
110	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 716-737.	0.6	40
111	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. Frontiers in Pharmacology, 2020, 11, 1258.	1.6	91

#	Article	IF	Citations
112	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nature Medicine, 2020, 26, 1701-1707.	15.2	315
113	SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. EBioMedicine, 2020, 59, 102951.	2.7	193
114	An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nature Communications, 2020, 11, 4207.	5.8	194
115	Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. Journal of Clinical Immunology, 2020, 40, 1082-1092.	2.0	48
116	A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nature Communications, 2020, 11, 4198.	5.8	132
117	Ramping up of SARS CoV-2 testing for the diagnosis of COVID-19 to better manage the next phase of pandemic and reduce the mortality in India. VirusDisease, 2020, 31, 432-440.	1.0	8
118	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. Hepatology, 2021, 74, 1088-1100.	3.6	58
119	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology, 2020, 11, 610688.	2.2	190
120	COVID-19: Coronavirus Vaccine Development Updates. Frontiers in Immunology, 2020, 11, 602256.	2.2	143
121	RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. Frontiers in Immunology, 2020, 11, 608460.	2.2	54
122	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications, 2020, 11, 6385.	5.8	103
123	Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. ERJ Open Research, 2020, 6, 00405-2020.	1.1	12
124	SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. Biomedicine and Pharmacotherapy, 2020, 130, 110629.	2.5	55
125	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. Pathogens, 2020, 9, 1027.	1.2	20
126	Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses, 2020, 12, 1390.	1.5	42
127	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. International Journal of Environmental Research and Public Health, 2020, 17, 8155.	1.2	63
128	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine, 2020, 136, 155256.	1.4	26
129	Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm. Biophysics (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.42	26

#	Article	IF	Citations
130	Germline immunoglobulin genes: Disease susceptibility genes hidden in plain sight?. Current Opinion in Systems Biology, 2020, 24, 100-108.	1.3	31
131	New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention. Frontiers in Cell and Developmental Biology, 2020, 8, 410.	1.8	96
132	Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Journal of Infectious Diseases, 2020, 222, 180-182.	1.9	12
133	The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals, 2020, 13, 96.	1.7	40
134	Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVIDâ€19. Clinical and Translational Science, 2020, 13, 835-837.	1.5	13
135	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. Vaccines, 2020, 8, 224.	2.1	47
136	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.	6.0	978
137	COVIDâ€19 vaccines: Knowing the unknown. European Journal of Immunology, 2020, 50, 939-943.	1.6	28
138	Prevention and treatment of COVIDâ€19 disease by controlled modulation of innate immunity. European Journal of Immunology, 2020, 50, 932-938.	1.6	59
139	Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Reviews Immunology, 2020, 20, 355-362.	10.6	1,963
140	COVID-19 in Newborns and Infantsâ€"Low Risk of Severe Disease: Silver Lining or Dark Cloud?. American Journal of Perinatology, 2020, 37, 845-849.	0.6	57
141	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerging Microbes and Infections, 2020, 9, 900-902.	3.0	89
142	Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell, 2020, 181, 1475-1488.e12.	13.5	405
143	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2020, 43, 102174.	0.9	62
144	Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nature Medicine, 2020, 26, 842-844.	15.2	2,083
145	Animal models for emerging coronavirus: progress and new insights. Emerging Microbes and Infections, 2020, 9, 949-961.	3.0	50
146	From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes and Infection, 2020, 22, 245-253.	1.0	36
147	SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. Infection, Genetics and Evolution, 2020, 84, 104384.	1.0	115

#	Article	IF	Citations
148	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology, 2020, 39, 2085-2094.	1.0	599
149	Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe, The, 2020, 1, e111-e118.	3.4	86
150	Cancer and COVID-19: Unmasking their ties. Cancer Treatment Reviews, 2020, 88, 102041.	3.4	82
151	Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. European Respiratory Journal, 2020, 56, 2001526.	3.1	292
152	Immunoregulation with mTOR inhibitors to prevent COVIDâ€19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. Journal of Medical Virology, 2020, 92, 1495-1500.	2.5	79
153	Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!. Clinical Immunology, 2020, 216, 108459.	1.4	91
154	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	6.6	1,387
155	Mild Course of COVIDâ€19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment. Arthritis and Rheumatology, 2020, 72, 1581-1582.	2.9	28
156	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell, 2020, 181, 1458-1463.	13.5	92
157	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115094.	0.8	293
158	Mechanistic inferences from clinical reports of SARS-CoV-2. Infectious Diseases, 2020, 52, 527-537.	1.4	4
159	SARS-CoV2 vaccines: Slow is fast. Science Advances, 2020, 6, eabc7428.	4.7	7
160	The role of <scp>SARSâ€CoV</scp>â€2 antibodies in <scp>COVID</scp>â€19: Healing in most, harm at times. Respirology, 2020, 25, 680-682.	1.3	27
161	A Comprehensive Updated Review on SARSâ€CoVâ€2 and COVIDâ€19. Journal of Clinical Pharmacology, 2020, 60, 954-975.	1.0	14
162	Facing SARS-CoV-2 outbreak in immunotherapy era. Future Oncology, 2020, 16, 1475-1485.	1.1	9
163	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. Frontiers in Immunology, 2020, 11, 1201.	2.2	15
164	Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. Journal of Infection, 2020, 81, 435-442.	1.7	140
165	mRNA Vaccines: Possible Tools to Combat SARS-CoV-2. Virologica Sinica, 2020, 35, 259-262.	1.2	17

#	Article	IF	Citations
166	Antibody-dependent enhancement and COVID-19: Moving toward acquittal. Clinical Immunology, 2020, 217, 108496.	1.4	17
167	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine, 2020, 56, 102822.	2.7	17
168	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. Journal of Autoimmunity, 2020, 114, 102506.	3.0	248
169	Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced â€˜PANICâ€™ attack. Journal of the Neurological Sciences, 2020, 415, 116935.	0.3	34
170	Anti-SARS-CoV-2 hyperimmune plasma workflow. Transfusion and Apheresis Science, 2020, 59, 102850.	0.5	9
171	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano, 2020, 14, 7760-7782.	7.3	289
172	Implications of COVID-19 in pediatric rheumatology. Rheumatology International, 2020, 40, 1193-1213.	1.5	35
173	Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature Biotechnology, 2020, 38, 789-791.	9.4	104
174	Considerations on biologicals for patients with allergic disease in times of the COVIDâ€19 pandemic: An EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2764-2774.	2.7	75
175	Severe COVID-19 and aging: are monocytes the key?. GeroScience, 2020, 42, 1051-1061.	2.1	118
176	Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA - Journal of the American Medical Association, 2020, 324, 259.	3.8	1,528
177	Dengue Fever, <scp>COVID</scp>â€19 (<scp>SARSâ€CoV</scp>â€2), and <scp>Antibodyâ€Dependent</scp> Enhancement (<scp>ADE</scp>): A Perspective. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 662-667.	1.1	89
178	Monoclonal antibody as a potential anti-COVID-19. Biomedicine and Pharmacotherapy, 2020, 129, 110337.	2.5	128
179	Dissecting antibody-mediated protection against SARS-CoV-2. Nature Reviews Immunology, 2020, 20, 392-394.	10.6	209
180	Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside. Frontiers in Cell and Developmental Biology, 2020, 8, 476.	1.8	27
181	Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics. Glycobiology, 2021, 31, 69-80.	1.3	51
182	Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. Journal of Neurology, 2020, 267, 2777-2789.	1.8	121
183	Cytokine storm induced by SARS-CoV-2. Clinica Chimica Acta, 2020, 509, 280-287.	0.5	405

#	Article	IF	Citations
184	COVID-19 Diagnostics, Tools, and Prevention. Diagnostics, 2020, 10, 409.	1.3	62
185	Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. Journal of Biosciences, 2020, 45, 1.	0.5	30
186	Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine. Journal of Molecular Liquids, 2020, 314, 113612.	2.3	50
187	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. International Journal of Biological Sciences, 2020, 16, 1718-1723.	2.6	225
188	Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 565-574.	4.6	2,704
189	Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clinical Infectious Diseases, 2020, 71, 2428-2446.	2.9	839
190	Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2027-2034.	2.9	2,214
191	Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines, 2020, 8, 153.	2.1	229
192	Collecting and evaluating convalescent plasma for COVIDâ€19 treatment: why and how?. Vox Sanguinis, 2020, 115, 488-494.	0.7	128
193	Childhood Multisystem Inflammatory Syndrome â€" A New Challenge in the Pandemic. New England Journal of Medicine, 2020, 383, 393-395.	13.9	183
194	COVID-19 Vaccines: â€œWarp Speedâ€•Needs Mind Melds, Not Warped Minds. Journal of Virology, 2020, 94, .	1.5	79
195	Does SARS-CoV-2 Trigger Stress-Induced Autoimmunity by Molecular Mimicry? A Hypothesis. Journal of Clinical Medicine, 2020, 9, 2038.	1.0	39
196	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity, 2020, 53, 442-455.e4.	6.6	281
197	Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. ELife, 2020, 9, .	2.8	80
198	Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding, and Antibody-dependent Enhancement (ADE). Clinics, 2020, 75, e1912.	0.6	64
199	A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. International Journal of Infectious Diseases, 2020, 98, 334-346.	1.5	58
201	In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies. Emerging Microbes and Infections, 2020, 9, 1523-1533.	3.0	9
202	Immunology of COVIDâ€19: Mechanisms, clinical outcome, diagnostics, and perspectivesâ€"A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2445-2476.	2.7	132

#	Article	IF	Citations
203	High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerging Microbes and Infections, 2020, 9, 1664-1670.	3.0	129
204	Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virologica Sinica, 2020, 35, 266-271.	1.2	602
205	The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 2020, 20, 363-374.	10.6	3,347
206	A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection. Clinical Immunology, 2020, 216, 108442.	1.4	11
207	COVIDâ€19 diagnosis and management: a comprehensive review. Journal of Internal Medicine, 2020, 288, 192-206.	2.7	924
208	Antibody therapies for the treatment of COVID-19. Antibody Therapeutics, 2020, 3, 101-108.	1.2	10
209	Employing drug delivery strategies to create safe and effective pharmaceuticals for ‹scp›COVID‹/scp›â€19. Bioengineering and Translational Medicine, 2020, 5, e10163.	3.9	7
210	Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Frontiers in Immunology, 2020, 11, 1049.	2.2	88
211	ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmunity Reviews, 2020, 19, 102536.	2.5	93
212	Effect of anti-TP0136 antibodies on the progression of lesions in an infected rabbit model. International Immunopharmacology, 2020, 83, 106428.	1.7	6
213	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 816-826.	4.6	182
214	COVID-19: Immunology and treatment options. Clinical Immunology, 2020, 215, 108448.	1.4	485
215	Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 2020, 71, 2255-2258.	2.9	283
216	Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome. Journal of Cellular and Molecular Medicine, 2020, 24, 6373-6384.	1.6	6
217	An effective CTL peptide vaccine for Ebola Zaire Based on Survivorsâ€™ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. Vaccine, 2020, 38, 4464-4475.	1.7	47
218	Good IgA Bad IgG in SARS-CoV-2 Infection?. Clinical Infectious Diseases, 2020, 71, 897-898.	2.9	23
219	The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes and Infection, 2020, 22, 165-167.	1.0	103
220	COVID-19 Convalescent Plasma: Now Is the Time for Better Science. Transfusion Medicine Reviews, 2020, 34, 141-144.	0.9	69

#	Article	IF	Citations
221	Progress and Concept for COVIDâ€19 Vaccine Development. Biotechnology Journal, 2020, 15, e2000147.	1.8	75
222	Hyperglycemia, hydroxychloroquine, and the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 770-775.	2.5	149
223	Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine, 2020, 55, 102768.	2.7	105
224	The potential danger of suboptimal antibody responses in COVID-19. Nature Reviews Immunology, 2020, 20, 339-341.	10.6	447
225	Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerging Microbes and Infections, 2020, 9, 833-836.	3.0	239
226	Anti-IL6R role in treatment of COVID-19-related ARDS. Journal of Translational Medicine, 2020, 18, 165.	1.8	82
227	Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: â€˜Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumoniaâ€™ by Guilpain et al. Annals of the Rheumatic Diseases, 2021, 80, e11-e11.	0.5	6
228	Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection. Archives of Medical Research, 2021, 52, 143-150.	1.5	5
229	Potential role of interferons in treating COVID-19 patients. International Immunopharmacology, 2021, 90, 107171.	1.7	55
230	Factors affecting antibody response to SARSâ€CoVâ€2 in patients with severe COVIDâ€19. Journal of Medical Virology, 2021, 93, 612-614.	2.5	13
231	Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2021, 17, 62-83.	1.4	25
232	The dynamic changes of serum IgM and IgG against SARSâ€CoVâ€2 in patients with COVIDâ€19. Journal of Medical Virology, 2021, 93, 924-933.	2.5	66
233	Magnitude and Kinetics of Antiâ€“Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Clinical Infectious Diseases, 2021, 72, 301-308.	2.9	175
234	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nature Immunology, 2021, 22, 74-85.	7.0	490
235	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 2021, 17, 46-64.	4.1	444
236	Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. Molecular and Cellular Proteomics, 2021, 20, 100058.	2.5	105
237	Severe acute respiratory syndromeâ€coronavirusâ€2 spike (S) protein based vaccine candidates: State of the art and future prospects. Reviews in Medical Virology, 2021, 31, e2183.	3.9	43
238	SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions. Molecular and Cellular Biochemistry, 2021, 476, 675-687.	1.4	38

#	Article	IF	Citations
239	Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVIDâ€19 convalescent plasma clinical trial. Journal of Internal Medicine, 2021, 289, 559-573.	2.7	41
240	Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219.	13.6	126
241	Coronavirus disease 2019 (COVIDâ€19): An overview of the immunopathology, serological diagnosis and management. Scandinavian Journal of Immunology, 2021, 93, e12998.	1.3	201
242	The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Research, 2021, 292, 198246.	1.1	53
243	Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVIDâ€19 patients. European Journal of Immunology, 2021, 51, 634-647.	1.6	27
244	Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. Journal of Allergy and Clinical Immunology, 2021, 147, 545-557.e9.	1.5	316
245	Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Archives of Disease in Childhood, 2021, 106, 429-439.	1.0	374
246	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomedicine and Pharmacotherapy, 2021, 133, 111008.	2.5	40
247	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	1.0	86
248	Combining Antivirals and Immunomodulators to Fight COVID-19. Trends in Immunology, 2021, 42, 31-44.	2.9	46
249	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Advanced Drug Delivery Reviews, 2021, 169, 168-189.	6.6	62
250	Viral targets for vaccines against COVID-19. Nature Reviews Immunology, 2021, 21, 73-82.	10.6	832
251	Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia. Inflammation Research, 2021, 70, 159-170.	1.6	17
252	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science, 2021, 371, .	6.0	244
253	Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. Journal of Intensive Care Medicine, 2021, 36, 18-41.	1.3	7
254	Informed consent disclosure to vaccine trial subjects of risk of COVIDâ€19 vaccines worsening clinical disease. International Journal of Clinical Practice, 2021, 75, e13795.	0.8	21
255	COVIDâ€19, varying genetic resistance to viral disease and immune tolerance checkpoints. Immunology and Cell Biology, 2021, 99, 177-191.	1.0	10
256	Challenges and prospects of COVIDâ€19 vaccine development based on the progress made in SARS and MERS vaccine development. Transboundary and Emerging Diseases, 2021, 68, 1111-1124.	1.3	35

#	Article	IF	Citations
257	Covidâ€19 and dengue: Double punches for dengueâ€endemic countries in Asia. Reviews in Medical Virology, 2021, 31, e2161.	3.9	118
258	The effect of drugs used in rheumatology for treating SARS-CoV2 infection. Expert Opinion on Biological Therapy, 2021, 21, 219-228.	1.4	6
259	The potential threat of multisystem inflammatory syndrome in children during the COVIDâ€19 pandemic. Pediatric Allergy and Immunology, 2021, 32, 17-22.	1.1	34
260	SARSâ€CoVâ€2: Mechanism of infection and emerging technologies for future prospects. Reviews in Medical Virology, 2021, 31, e2168.	3.9	28
261	Human postâ€infection serological response to the spike and nucleocapsid proteins of SARSâ€CoVâ€2. Influenza and Other Respiratory Viruses, 2021, 15, 7-12.	1.5	4
262	Clinical analysis and pluripotent stem cells-based model reveal possible impacts of ACE2 and lung progenitor cells on infants vulnerable to COVID-19. Theranostics, 2021, 11, 2170-2181.	4.6	14
263	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Frontiers in Immunology, 2020, 11, 607583.	2.2	12
264	Childhood Multisystem Inflammatory Syndrome: An Emerging Disease with Prominent Cardiovascular Involvementâ€"A Scoping Review. SN Comprehensive Clinical Medicine, 2021, 3, 48-59.	0.3	22
265	Severe COVID-19: Immunosuppression or Hyperinflammation?. Shock, 2021, 56, 188-199.	1.0	20
267	COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 2021, 184, 476-488.e11.	13.5	586
268	COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. Molecular Diversity, 2022, 26, 629-645.	2.1	15
269	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nature Communications, 2021, 12, 372.	5.8	369
270	Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels. Frontiers in Molecular Biosciences, 2020, 7, 605862.	1.6	4
271	COVID-19 Vaccine: Critical Questions with Complicated Answers. Biomolecules and Therapeutics, 2021, 29, 1-10.	1.1	40
272	Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. Clinical Infectious Diseases, 2021, 73, e719-e734.	2.9	16
274	Antibodies to neutralising epitopes synergistically block the interaction of the receptorâ€binding domain of SARSâ€CoVâ€2 to ACE 2. Clinical and Translational Immunology, 2021, 10, e1260.	1.7	13
275	Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19. BMC Medicine, 2021, 19, 19.	2.3	14
277	Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerging Microbes and Infections, 2021, 10, 664-676.	3.0	69

#	Article	IF	Citations
278	Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. MAbs, 2021, 13, 1953683.	2.6	20
279	A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. Immunologic Research, 2021, 69, 18-25.	1.3	16
280	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. Comparative Medicine, 2021, 71, 411-432.	0.4	11
281	CORONAVIRUSES â€“ HOW PROTEIN INTERACTIONS CHANGED OUR PERCEPTION OF THE WORLD. Postepy Mikrobiologii, 2021, 60, 121-135.	0.1	0
282	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses, 2021, 13, 134.	1.5	56
283	The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 2021, 11, 1690-1702.	4.6	71
284	Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis. Immune Network, 2021, 21, e1.	1.6	9
286	SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1.	1.9	104
287	Immune dysregulation and system pathology in COVID-19. Virulence, 2021, 12, 918-936.	1.8	74
288	Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Frontiers in Immunology, 2021, 12, 632890.	2.2	53
289	ÂÂÂÂÂÂÂA type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDSÂÂÂ. Wellcome Open Research, 2021, 6, 38.	0.9	29
291	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nature Communications, 2021, 12, 1152.	5.8	71
292	COVID-19 and immunity: quo vadis?. International Immunology, 2021, 33, 507-513.	1.8	5
293	Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Frontiers in Immunology, 2021, 12, 640093.	2.2	93
294	Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India. Frontiers in Genetics, 2021, 12, 637362.	1.1	5
295	Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin. Internal Medicine, 2021, 60, 457-461.	0.3	6
296	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Reports, 2021, 34, 108699.	2.9	110
297	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. International Reviews of Immunology, 2022, 41, 171-206.	1.5	30

#	Article	IF	Citations
298	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. Current Drug Targets, 2021, 22, 254-281.	1.0	27
301	Identification of HLA-A*02:01-Restricted Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 That May Be Natural Targets of CD8 ⁺ T Cell Recognition In Vivo. Journal of Virology, 2021, 95, .	1.5	20
302	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Frontiers in Immunology, 2021, 12, 574425.	2.2	38
303	A look-back at convalescent plasma to treat COVID-19. Transfusion and Apheresis Science, 2021, 60, 103063.	0.5	11
304	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Npj Vaccines, 2021, 6, 28.	2.9	507
305	Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes. Viruses, 2021, 13, 333.	1.5	14
306	AI Aided Design of Epitope-Based Vaccine for the Induction of Cellular Immune Responses Against SARS-CoV-2. Frontiers in Genetics, 2021, 12, 602196.	1.1	5
308	Serum Î²2-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?. PLoS ONE, 2021, 16, e0247758.	1.1	12
309	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy, 2021, Volume 10, 63-85.	2.7	40
310	Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs. Vaccines, 2021, 9, 240.	2.1	20
311	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. Scientific Reports, 2021, 11, 5934.	1.6	26
312	The conundrum of current anti-SARS-CoV-2 vaccines. Cytokine and Growth Factor Reviews, 2021, 60, 46-51.	3.2	6
313	Antibodies: Friends, Foes, or Both? Lessons From COVID-19 for the Rheumatologist. Journal of Clinical Rheumatology, 2022, 28, e263-e269.	0.5	0
315	SARSâ€CoVâ€2â€related multisystem inflammatory syndrome in an immunocompromised child with leukemia. Pediatric Blood and Cancer, 2021, 68, e28995.	0.8	10
316	Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data. Frontiers in Artificial Intelligence, 2021, 4, 630955.	2.0	13
317	Monocytes and macrophages in COVID-19: Friends and foes. Life Sciences, 2021, 269, 119010.	2.0	97
318	Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Reports, 2021, 34, 108915.	2.9	127
320	Clinical Characteristics of Paediatric Hyperinflammatory Syndrome in the Era of Corona Virus Disease 2019 (COVID-19). Indian Journal of Clinical Biochemistry, 2021, 36, 404-415.	0.9	4

#	Article	IF	Citations
322	The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 37-46.	0.2	5
323	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nature Communications, 2021, 12, 1577.	5.8	73
324	An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndromeâ€“Coronavirus. Frontiers in Molecular Biosciences, 2021, 8, 637550.	1.6	8
325	COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire. Frontiers in Immunology, 2021, 12, 649567.	2.2	14
327	Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo. Scientific Reports, 2021, 11, 5774.	1.6	20
328	COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 2021, 170, 1-25.	6.6	262
329	High neutralizing potency of swine glycoâ€humanized polyclonal antibodies against SARSâ€CoVâ€2. European Journal of Immunology, 2021, 51, 1412-1422.	1.6	21
330	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Reports, 2021, 34, 108837.	2.9	23
331	Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. Scientific Reports, 2021, 11, 7052.	1.6	113
332	Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study. Journal of Clinical Medicine, 2021, 10, 1771.	1.0	3
333	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity, 2021, 54, 815-828.e5.	6.6	34
334	Temporal viral loads in respiratory and gastrointestinal tract and serum antibody responses during SARS-CoV-2 infection in an Italian pediatric cohort. Clinical Immunology, 2021, 225, 108695.	1.4	2
336	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	5.1	87
337	Natural mucosal barriers and COVID-19 in children. JCI Insight, 2021, 6, .	2.3	124
338	Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus. Frontiers in Immunology, 2021, 12, 580147.	2.2	2
339	A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines, 2021, 9, 431.	2.1	18
341	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine, 2021, 180, 106355.	1.3	25
342	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	5.8	125

#	Article	IF	Citations
343	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine, 2021, 66, 103291.	2.7	15
344	Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19. Infection, Genetics and Evolution, 2021, 89, 104712.	1.0	9
345	Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2. Communications Biology, 2021, 4, 500.	2.0	12
347	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunologic Research, 2021, 69, 213-224.	1.3	27
348	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microbial Cell Factories, 2021, 20, 88.	1.9	37
349	Capturing Cytokines with Advanced Materials: A Potential Strategy to Tackle COVIDâ€19 Cytokine Storm. Advanced Materials, 2021, 33, e2100012.	11.1	43
350	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	1.8	47
351	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Reports Medicine, 2021, 2, 100230.	3.3	99
352	Application of a recombinant replicase to localize the Trionyx sinensis hemorrhagic syndrome virus and evaluate its effects on antiviral genes of T. sinensis. Journal of Zhejiang University: Science B, 2021, 22, 295-304.	1.3	3
355	RBD-specific polyclonal F(abÂ')2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. EClinicalMedicine, 2021, 34, 100843.	3.2	41
356	CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. Scientific Reports, 2021, 11, 8761.	1.6	41
357	Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. International Immunopharmacology, 2021, 93, 107364.	1.7	54
358	COVID-19 in Immunosuppressed Children. Frontiers in Pediatrics, 2021, 9, 629240.	0.9	30
359	A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage. Cell Reports, 2021, 35, 109107.	2.9	18
360	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. Pathogens, 2021, 10, 636.	1.2	2
361	Diagnostic performance of an automated chemiluminescence immunoassay for SARS-CoV-2 IgG and IgM antibodies detection: A real life experience. Practical Laboratory Medicine, 2021, 25, e00227.	0.6	6
362	Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2021, 39, 3053-3066.	1.7	66
363	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials, 2021, 22, 323.	0.7	21

#	Article	IF	Citations
364	Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein. Nature Communications, 2021, 12, 2790.	5.8	26
365	The understanding of the immunopathology in COVID-19 infection. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 255-263.	0.6	5
366	Physiological and Pathological Inflammation Induced by Antibodies and Pentraxins. Cells, 2021, 10, 1175.	1.8	9
367	Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Viruses, 2021, 13, 1037.	1.5	20
368	ÂÂÂÂÂÂA type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDSÂÂÂ. Wellcome Open Research, 2021, 6, 38.	0.9	35
369	Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. Frontiers in Immunology, 2021, 12, 673699.	2.2	16
370	Histomorphological patterns of regional lymph nodes in COVID-19 lungs. Der Pathologe, 2021, 42, 89-97.	0.7	19
371	Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus. JCI Insight, 2021, 6, .	2.3	7
372	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	2.9	198
373	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVIDâ€19 vaccines in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 72-82.	2.7	11
374	To vaccinate or not to vaccinate; that is the question! (New insights on COVID-19 Vaccination). Current Molecular Medicine, 2021, 21, .	0.6	1
375	Development of a highâ€sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARSâ€CoVâ€2 spike glycoprotein in serum and saliva. Immunology, 2021, 164, 135-147.	2.0	35
376	High titers and low fucosylation of early human antiâ€“SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Science Translational Medicine, 2021, 13, .	5.8	166
377	Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19. Scientific Reports, 2021, 11, 9825.	1.6	17
378	Safety and Considerations of the COVID-19 Vaccine Massive Deployment. Virologica Sinica, 2021, 36, 1097-1103.	1.2	3
379	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. Molecules and Cells, 2021, 44, 392-400.	1.0	22
380	A Step Toward Optimizing Regenerative Medicine Principle to Combat COVID-19. Annals of the National Academy of Medical Sciences (India), 2021, 57, 202-213.	0.2	0
381	Prolonged SARS-CoV-2Âcell culture replication in respiratory samples from patients with severe COVID-19. Clinical Microbiology and Infection, 2021, 27, 886-891.	2.8	51

#	Article	IF	Citations
382	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Human Gene Therapy, 2021, 32, 541-562.	1.4	9
383	COVID-19 vaccines: Frequently asked questions and updated answers. Infectious Diseases Now, 2021, 51, 319-333.	0.7	10
384	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). BioMed Research International, 2021, 2021, 1-20.	0.9	13
385	The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing. Life Sciences, 2021, 274, 119289.	2.0	9
386	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE, 2021, 16, e0253487.	1.1	76
387	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennye Tehnologii V Medicine, 2021, 13, 81.	0.4	4
388	An overview of some potential immunotherapeutic options against COVID-19. International Immunopharmacology, 2021, 95, 107516.	1.7	7
389	Is SARS-CoV-2 Spike glycoprotein impairing macrophage function via Î±7-nicotinic acetylcholine receptors?. Food and Chemical Toxicology, 2021, 152, 112184.	1.8	10
390	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduction and Targeted Therapy, 2021, 6, 233.	7.1	203
391	Severe Clinical Worsening in COVID-19 and Potential Mechanisms of Immune-Enhanced Disease. Frontiers in Medicine, 2021, 8, 637642.	1.2	7
392	SARS-CoV-2: Unique Challenges of the Virus and Vaccines. Immunological Investigations, 2021, 50, 802-809.	1.0	12
393	Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2021, 15, 670298.	1.8	40
394	What gastroenterologists should know about SARSâ€“CoV 2 vaccine: World Endoscopy Organization perspective. United European Gastroenterology Journal, 2021, 9, 787-796.	1.6	4
395	Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcÎ³RIIA and FcÎ±RI. Frontiers in Immunology, 2021, 12, 700429.	2.2	13
397	Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19. Scientific Reports, 2021, 11, 11462.	1.6	11
398	Evaluation of the relationship between macrophage migration inhibitory factor level and clinical course in patients with COVIDâ€19 pneumonia. Journal of Medical Virology, 2021, 93, 6519-6524.	2.5	14
399	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. Journal of Immunology, 2021, 207, 878-887.	0.4	30
400	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Frontiers in Immunology, 2021, 12, 701501.	2.2	157

#	Article	IF	Citations
401	Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Reports Medicine, 2021, 2, 100329.	3.3	65
402	Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Reports, 2021, 36, 109414.	2.9	75
403	Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduction and Targeted Therapy, 2021, 6, 270.	7.1	20
404	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. IScience, 2021, 24, 102699.	1.9	15
405	Pathogenesis of Coronaviruses Through Human Monocytes and Tissue Macrophages. Viral Immunology, 2021, 34, 597-606.	0.6	3
406	Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins. Cell Reports, 2021, 36, 109391.	2.9	32
407	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies. Journal of Infection and Chemotherapy, 2021, 27, 1063-1067.	0.8	9
408	SARS-CoV-2 Infection and Antibody-Dependent Enhancement. Studies in Computational Intelligence, 2022, , 101-113.	0.7	0
409	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. ACS Central Science, 2021, 7, 1368-1380.	5.3	21
410	Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality. Frontiers in Immunology, 2021, 12, 668725.	2.2	49
411	Immune cell profiling and antibody responses in patients with COVID-19. BMC Infectious Diseases, 2021, 21, 646.	1.3	17
412	Analysis of the dynamic relationship between immune profiles and the clinical features of patients with COVID-19. Annals of Translational Medicine, 2021, 9, 1118-1118.	0.7	3
413	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. Journal of Advanced Research, 2021, 31, 49-60.	4.4	27
414	Peculiarities of Seroprovalence to SARS-CoV-2 in the Population of the Middle and Southern Urals in the Early Period of the COVID-19 Pandemic. Epidemiologiya I Vaktsinoprofilaktika, 2021, 20, 8-18.	0.2	5
416	Non-human primate models of human respiratory infections. Molecular Immunology, 2021, 135, 147-164.	1.0	17
417	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0035021.	1.4	18
418	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Reports, 2021, 36, 109433.	2.9	75
419	Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks. Vaccines, 2021, 9, 747.	2.1	14

#	Article	IF	Citations
421	Synopsis of Pharmotechnological Approaches in Diagnostic and Management Strategies for Fighting Against COVID-19. Current Pharmaceutical Design, 2021, 27, 4086-4099.	0.9	3
422	Monocytes and Macrophages in COVID-19. Frontiers in Immunology, 2021, 12, 720109.	2.2	168
423	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	2.9	241
424	A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. Innovation(China), 2021, 2, 100140.	5.2	19
425	Putative Role of Vitamin D for COVID-19 Vaccination. International Journal of Molecular Sciences, 2021, 22, 8988.	1.8	32
426	SARS CoV-2 Vaccination Autoimmunity, Antibody Dependent Covid-19 Enhancement and Other Potential Risks: Beneath the Tip of the Iceberg. International Journal of Pulmonary & Respiratory Sciences, 2021, 5, .	0.1	2
428	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Vaccines, 2021, 9, 869.	2.1	17
430	Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19. Vaccines, 2021, 9, 928.	2.1	12
431	Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathogens, 2021, 17, e1009758.	2.1	17
432	Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era. Infectious Microbes & Diseases, 2021, 3, 125-133.	0.5	0
433	Astaxanthin protective barrier and its ability to improve the health in patients with COVID-19. Iranian Journal of Microbiology, 2021, 13, 434-441.	0.8	10
434	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Frontiers in Immunology, 2021, 12, 719023.	2.2	28
435	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3237-3248.	2.0	4
436	Cell and molecular level of strategy of COVID-19 to induce immunodeficiency. Possible therapeutic solutions. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2021, 98, 450-467.	0.3	2
437	Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters. Frontiers in Microbiology, 2021, 12, 720437.	1.5	15
438	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. Microorganisms, 2021, 9, 1964.	1.6	13
439	Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination. Human Vaccines and Immunotherapeutics, 2021, 17, 4121-4125.	1.4	3
440	Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus. Current Microbiology, 2021, 78, 3813-3828.	1.0	4

#	Article	IF	Citations
442	Renal Involvement in Pediatric Patients with COVID-19: An Up-to-date Review. Current Pediatric Reviews, 2021, 17, 253-263.	0.4	4
443	The immune response to SARS-CoV-2 and COVID-19 immunopathology â€“ Current perspectives. Pulmonology, 2021, 27, 423-437.	1.0	118
444	Endocytosis and Transcytosis of SARS-CoV-2 Across the Intestinal Epithelium and Other Tissue Barriers. Frontiers in Immunology, 2021, 12, 636966.	2.2	23
445	The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduction and Targeted Therapy, 2021, 6, 340.	7.1	48
446	Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development. BioDrugs, 2021, 35, 505-515.	2.2	16
447	Impact of rituximab on COVID-19 outcomes. Annals of Hematology, 2021, 100, 2805-2812.	0.8	46
448	To study heterogeneity in SARS-CoV-2 IgG response titre in patients recovered from COVID-19. Monaldi Archives for Chest Disease, 2021, , .	0.3	0
449	Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 â€“ A case series. Transfusion and Apheresis Science, 2021, , 103278.	0.5	5
450	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. Frontiers in Immunology, 2021, 12, 708848.	2.2	7
451	Profile of Immunoglobulin G N-Glycome in COVID-19 Patients: A Case-Control Study. Frontiers in Immunology, 2021, 12, 748566.	2.2	33
453	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Frontiers in Cellular and Infection Microbiology, 2021, 11, 690621.	1.8	60
454	Highly active engineered IgG3 antibodies against SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
455	Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. Human Immunology, 2021, 82, 733-745.	1.2	47
456	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	2
457	Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Paediatric Drugs, 2021, 23, 119-129.	1.3	62
458	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2â€“specific monoclonal antibody CR3022. JCI Insight, 2021, 6, .	2.3	34
459	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. Immune Network, 2021, 21, e8.	1.6	3
460	Distinct Disease Severity Between Children and Older Adults With Coronavirus Disease 2019 (COVID-19): Impacts of ACE2 Expression, Distribution, and Lung Progenitor Cells. Clinical Infectious Diseases, 2021, 73, e4154-e4165.	2.9	42

#	Article	IF	Citations
461	Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature, 2021, 590, 635-641.	13.7	524
462	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. Science China Life Sciences, 2020, 63, 1833-1849.	2.3	29
463	Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 2020, 181, 1489-1501.e15.	13.5	3,220
464	Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. Journal of Controlled Release, 2020, 328, 112-126.	4.8	35
465	Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. Journal of Clinical Virology, 2020, 127, 104388.	1.6	37
466	Coronaviruses pandemics: Can neutralizing antibodies help?. Life Sciences, 2020, 255, 117836.	2.0	24
467	Consensus summary report for CEPI/BC March 12â€“13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine, 2020, 38, 4783-4791.	1.7	102
468	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. ACS Biomaterials Science and Engineering, 2021, 7, 1742-1764.	2.6	16
469	Chinaâ€™s coronavirus vaccines are leaping ahead â€“ but face challenges as virus wanes. Nature, 2020, 584, 17-18.	13.7	3
470	Dysregulation of type I interferon responses in COVID-19. Nature Reviews Immunology, 2020, 20, 397-398.	10.6	374
471	Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs. Scientific Reports, 2020, 10, 22375.	1.6	56
473	Natural history of COVID-19 and therapeutic options. Expert Review of Clinical Immunology, 2020, 16, 1159-1184.	1.3	101
474	Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. Journal of Infectious Diseases, 2021, 223, 981-984.	1.9	62
537	<scp>COVID</scp>â€19: are neutralizing antibodies neutralizing enough?. Transfusion, 2020, 60, 1602-1603.	0.8	13
538	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. , 2020, 8, e000892.		43
539	Early safety indicators of COVID-19 convalescent plasma in 5000 patients. Journal of Clinical Investigation, 2020, 130, 4791-4797.	3.9	386
540	The lethal sex gap: COVID-19. Immunity and Ageing, 2020, 17, 13.	1.8	68
541	A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. American Journal of Case Reports, 2020, 21, e927812.	0.3	39

#	Article	IF	Citations
542	Antibody testing for COVID-19: A report from theÂNational COVID Scientific Advisory Panel. Wellcome Open Research, 2020, 5, 139.	0.9	179
543	Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19. Wellcome Open Research, 0, 5, 115.	0.9	7
544	The impact of the global distribution of bats on mortality in COVID-19 patients. Microbiology Independent Research Journal, 2020, 7, 42-48.	0.2	2
545	Why does COVID-19 disproportionately affect older people?. Aging, 2020, 12, 9959-9981.	1.4	708
546	Multisystem Inflammatory Syndrome in Children Related to COVID-19: the First Case in Korea. Journal of Korean Medical Science, 2020, 35, e391.	1.1	27
547	Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches. Frontiers in Pharmacology, 2020, 11, 592169.	1.6	9
548	Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. Journal of Microbiology and Biotechnology, 2020, 30, 1109-1115.	0.9	12
549	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian Journal of Ophthalmology, 2020, 68, 693.	0.5	78
550	Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 456-462.	0.2	7
551	Coronavirus-2019 Disease (COVID-19) in children. Medeniyet Medical Journal, 2020, 35, 242-252.	0.4	4
552	Antibody responses in COVID-19 patients. Journal of Biomedical Research, 2020, 34, 410.	0.7	7
553	Antibody dependent enhancement: Unavoidable problems in vaccine development. Advances in Immunology, 2021, 151, 99-133.	1.1	25
554	A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110501.	1.0	26
555	When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. Frontiers in Immunology, 2021, 12, 692598.	2.2	7
556	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. Npj Vaccines, 2021, 6, 125.	2.9	17
558	Personalized therapy: can it tame the COVID-19 monster?. Personalized Medicine, 2021, 18, 583-593.	0.8	4
560	Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics, 2021, 1, 337-356.	2.3	58
563	Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study. PLoS ONE, 2021, 16, e0258255.	1.1	4

#	Article	IF	Citations
564	ASTHMA AND COVID-19: THE EOSINOPHILIC LINK. Qeios, 0, , .	0.0	7
566	Vantaggi, limiti e prospettive dei test sierologici nell'infezione da SARS-CoV-2 (COVID-19). Rivista Italiana Della Medicina Di Laboratorio, 2020, 16, .	0.2	0
569	Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19. Journal of Bacteriology and Virology, 2020, 50, 76-96.	0.0	1
570	Biological Therapy During COVID-19. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2020, 19, 116-122.	0.1	2
572	Original SARS-CoV-2 vaccine model. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 128-132.	0.1	0
573	Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. , 2022, 233, 108027.		2
575	Three Probable Pediatrics COVID-19 Cases with Kawasaki-like Disease: A Case Series with Fallow-up. Archives of Pediatric Infectious Diseases, 2020, 9, .	0.1	0
577	Ð'Ð»Ð¸ÑĐ½Ð¸Ð¼ Ð³Ð»Ð¾Ð±Ð°Ð»ÑŒÐ½Ð¾Ð³Ð¾ Ñ€Ð°ÑÐ¿Ñ€Ð¾ÑÑ‚Ñ€Ð°Ð½ÐµÐ½Ð¸Ñ Ð»ÐµÐ³ÐºÐ¾ÑÑ‚Ð¸ Ð¸ Ð½ÐµÐ°		
578	Biological Disasters: An Overview of the Covid-19 Pandemic in the First Quarter of 2021. Afet Ve Risk Dergisi, 2021, 4, 163-182.	0.2	6
579	Development of an Inactivated Vaccine against SARS CoV-2. Vaccines, 2021, 9, 1266.	2.1	23
581	CaracterÃsticas y especializaciÃ³n de la respuesta inmunitaria en la COVID-19. Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico, 2020, 63, 7-18.	0.0	6
586	Coronavirus and Homo Sapiens. Journal of Cardiac Critical Care TSS, 0, , .	0.0	0
587	Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. Current Opinion in HIV and AIDS, 2020, 15, 325-327.	1.5	0
592	Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions. Clinics, 2021, 76, e2818.	0.6	2
593	Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(abâ€²)2 fragment derived from equine polyclonal antibodies. Toxicology and Applied Pharmacology, 2022, 434, 115796.	1.3	3
594	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses â€" are we our own worst enemy?. Nature Reviews Immunology, 2022, 22, 47-56.	10.6	118
595	Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVIDâ€19. Archiv Der Pharmazie, 2022, 355, e2100367.	2.1	9
596	Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. Journal of Nanobiotechnology, 2021, 19, 391.	4.2	17

#	Article	IF	Citations
597	Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduction and Targeted Therapy, 2021, 6, 389.	7.1	21
598	Pathogenesis of Respiratory Viral and Fungal Coinfections. Clinical Microbiology Reviews, 2022, 35, e0009421.	5.7	64
599	Alveolar macrophages: novel therapeutic targets for respiratory diseases. Expert Reviews in Molecular Medicine, 2021, 23, e18.	1.6	10
600	Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study. Indian Journal of Critical Care Medicine, 2022, 26, 39-42.	0.3	25
602	Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges. Recent Patents on Biotechnology, 2022, 16, 64-78.	0.4	3
603	Redox Homeostasis and Immune Alterations in Coronavirus Disease-19. Biology, 2022, 11, 159.	1.3	10
604	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine, 2022, 75, 103762.	2.7	32
605	SARS-CoV-2 and the Host Cell: A Tale of Interactions. Frontiers in Virology, 2022, 1, .	0.7	37
606	Multisystem inflammatory syndrome in neonates (MIS-N) associated with SARS-CoV2 infection: a case series. European Journal of Pediatrics, 2022, 181, 1883-1898.	1.3	37
607	Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19â€“convalescent individuals. Journal of Allergy and Clinical Immunology, 2022, 149, 1225-1241.	1.5	5
608	The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19. Frontiers in Immunology, 2021, 12, 816745.	2.2	9
609	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science, 2022, 29, 1.	2.6	144
610	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	15.2	206
611	The T cell immune response against SARS-CoV-2. Nature Immunology, 2022, 23, 186-193.	7.0	785
612	Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective. Journal of the Indian Institute of Science, 2022, , 1-17.	0.9	12
614	Predicted impact of the viral mutational landscape on the cytotoxic response against SARS-CoV-2. PLoS Computational Biology, 2022, 18, e1009726.	1.5	11
615	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. Frontiers in Immunology, 2022, 13, 801522.	2.2	73
617	A Review of Coronaviruses Associated With Kawasaki Disease: Possible Implications for Pathogenesis of the Multisystem Inflammatory Syndrome Associated With COVID-19. Clinical Medicine Insights Pediatrics, 2022, 16, 117955652210753.	0.7	8

#	Article	IF	Citations
619	COVID-19 Vaccine: Between Myth and Truth. Vaccines, 2022, 10, 349.	2.1	12
621	COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines. Children, 2022, 9, 249.	0.6	29
622	Post-COVID-19 HSV encephalitis: a review. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 222-227.	0.2	11
623	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. Frontiers in Microbiology, 2022, 13, 845316.	1.5	8
624	Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS ONE, 2022, 17, e0257930.	1.1	12
625	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. Frontiers in Immunology, 2022, 13, 845887.	2.2	13
626	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. Frontiers in Immunology, 2022, 13, 835104.	2.2	28
627	Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcÎ³RIIB and virus-antibody complex with bivalent interaction. Communications Biology, 2022, 5, 262.	2.0	26
629	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. Signal Transduction and Targeted Therapy, 2022, 7, 69.	7.1	19
630	NETosis and SARS-COV-2 infection related thrombosis: a narrative review. Thrombosis Journal, 2022, 20, 13.	0.9	20
631	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine, 2022, 77, 103904.	2.7	93
632	MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2. Computers in Biology and Medicine, 2022, 145, 105509.	3.9	2
633	Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. Frontiers in Immunology, 2022, 13, 882856.	2.2	4
634	Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. Frontiers in Immunology, 2022, 13, 882972.	2.2	32
635	The role of antigen-presenting cells in the pathogenesis of COVID-19. Pathology Research and Practice, 2022, 233, 153848.	1.0	17
636	Effectiveness and Safety of COVID-19 Vaccine. Trends in the Sciences, 2021, 26, 10_18-10_25.	0.0	0
637	Covid-19 pandemic: What is the truth?. , 2021, 12, 591.		3
638	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. Exploration of Immunology, 0, , 440-460.	1.7	0

#	Article	IF	Citations
646	Immune response and cytokine storm in SARS-CoV-2 infection: Risk factors, ways of control and treatment. European Journal of Inflammation, 2022, 20, 1721727X2210989.	0.2	2
648	Potential of Antibody-Dependent Cellular Cytotoxicity in Acute and Recovery Phases of SARS-CoV-2 Infection. Infectious Diseases & Immunity, 2022, 2, 74-82.	0.2	4
649	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. Frontiers in Immunology, 2022, 13, 843928.	2.2	25
650	A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model. Frontiers in Immunology, 2022, 13, .	2.2	3
651	Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19. Journal of Microbiology, Immunology and Infection, 2022, 55, 1094-1100.	1.5	9
652	Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. Antibodies, 2022, 11, 35.	1.2	3
653	Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review. Alexander Saltanov Intensive Care Herald, 2022, , 108-120.	0.2	3
654	IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes. Cell Reports, 2022, 39, 110904.	2.9	9
655	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. Expert Review of Vaccines, 2022, 21, 1071-1086.	2.0	3
656	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses, 2022, 14, 1089.	1.5	9
657	Is COVID-19 really a geriatric syndrome?. Ageing Research Reviews, 2022, 79, 101657.	5.0	1
658	COVID-19 infection: an overview on cytokine storm and related interventions. Virology Journal, 2022, 19, .	1.4	223
659	Development and Evaluation about â€œ2nd-waveâ€•COVID-19 Vaccines. Yakugaku Zasshi, 2022, 142, 619-627.	0.0	1
660	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	2.0	1
661	Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. Microbiology Spectrum, 2022, 10, .	1.2	3
662	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Translational Research, 2022, 249, 13-27.	2.2	5
663	Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic. Biosafety and Health, 2022, 4, 347-363.	1.2	2
664	Strategies to fight COVID-19: Beyond the difference between SARS-CoV-2 and Influenza virus. International Journal of Sexual and Reproductive Health Care, 2022, 5, 016-029.	0.1	0

#	Article	IF	Citations
665	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nature Communications, 2022, 13, .	5.8	22
666	COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. Seminars in Arthritis and Rheumatism, 2022, 55, 152047.	1.6	24
667	Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?. International Immunopharmacology, 2022, 110, 108943.	1.7	6
668	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	1.7	10
669	Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. Scientific Reports, 2022, 12, .	1.6	4
670	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
671	Alveolar macrophages: Achillesâ€™ heel of SARS-CoV-2 infection. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	15
672	Vaccines platforms and COVID-19: what you need to know. Tropical Diseases, Travel Medicine and Vaccines, 2022, 8, .	0.9	16
673	Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. Frontiers in Immunology, 0, 13, .	2.2	2
674	An ACE2-IgG4 Fc Fusion Protein Demonstrates Strong Binding to All Tested SARS-CoV-2 Variants and Reduced Lung Inflammation in Animal Models of SARS-CoV-2 and Influenza. Pathogens and Immunity, 2022, 7, 104-121.	1.4	1
675	Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Frontiers in Microbiology, 0, 13, .	1.5	12
676	Host and microbiome features of secondary infections in lethal covid-19. IScience, 2022, 25, 104926.	1.9	10
677	Nanobionics: From plant empowering to the infectious disease treatment. Journal of Controlled Release, 2022, 349, 890-901.	4.8	3
678	Clinical profile and immediate outcome of the multisystem inflammatory syndrome in children: Retrospective observational single center study from the United Arab Emirates. Journal of Pediatric Critical Care, 2022, 9, 116.	0.0	1
679	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
680	The role of B cells in COVID-19 infection and vaccination. Frontiers in Immunology, 0, 13, .	2.2	25
681	Broadâ€spectrum antiviral activity of Spatholobus suberectus Dunn against <scp>SARSâ€CoV</scp>â€2, <scp>SARSâ€CoV</scp>â€1, <scp>H5N1</scp>, and other enveloped viruses. Phytotherapy Research, 2022, 36, 3232-3247.	2.8	12
682	Mitochondrial regulation of acute extrafollicular Bâ€cell responses to COVIDâ€19 severity. Clinical and Translational Medicine, 2022, 12, .	1.7	3

#	Article	IF	Citations
683	Focus on long non-coding RNA MALAT1: Insights into acute and chronic lung diseases. Frontiers in Genetics, 0, 13, .	1.1	8
685	SARSâ€CoVâ€2 vaccines: A doubleâ€edged sword throughout rapid evolution of COVIDâ€19. Cell Biology International, 2022, 46, 2009-2017.	1.4	3
686	The frequency and seasonal distribution of viral infection in patients with community-acquired pneumonia and its impact on the prognosis. Acute and Critical Care, 0, , .	0.6	0
687	SARS-CoV-2 and HIV-1: So Different yet so Alike. Immune Response at the Cellular and Molecular Level. International Journal of Medical Sciences, 2022, 19, 1787-1795.	1.1	6
688	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
689	Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. PLoS ONE, 2022, 17, e0272594.	1.1	1
690	Highly pathogenic coronaviruses and the kidney. Biomedicine and Pharmacotherapy, 2022, 156, 113807.	2.5	1
691	Severe acute respiratory syndrome (SARS). , 2023, , 53-124.		0
692	Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine. ACS Infectious Diseases, 2022, 8, 2586-2593.	1.8	2
693	Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Emerging Microbes and Infections, 2023, 12, .	3.0	3
694	A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Emerging Microbes and Infections, 2023, 12, .	3.0	5
695	Impaired VEGF-A-Mediated Neurovascular Crosstalk Induced by SARS-CoV-2 Spike Protein: A Potential Hypothesis Explaining Long COVID-19 Symptoms and COVID-19 Vaccine Side Effects?. Microorganisms, 2022, 10, 2452.	1.6	8
697	SARS-CoV-2 infection of phagocytic immune cells and COVID-19 pathology: Antibody-dependent as well as independent cell entry. Frontiers in Immunology, 0, 13, .	2.2	11
698	JMJD3 Is Required for Acute Pancreatitis and Pancreatitis-Associated Lung Injury. Journal of Immunology, 2023, 210, 180-190.	0.4	3
699	Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content. Viruses, 2023, 15, 62.	1.5	0
700	Coagulopathy and the humoral response against viral proteins in patients at different stages of COVID-19. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	0.8	0
701	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology, 2023, 12, 177.	1.3	11
702	Predictive analytics of genetic variation in the COVID-19 genome sequence: a data science perspective. , 2023, , 229-247.		0

#	Article	IF	Citations
703	SARS-CoV-2 infection and immune responses. AIMS Microbiology, 2023, 9, 245-276.	1.0	2
704	Non-neutralizing antibodies to SARS-Cov-2-related linear epitopes induce psychotic-like behavior in mice. Frontiers in Molecular Neuroscience, 0, 16, .	1.4	1
705	An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection. Nature Materials, 2023, 22, 903-912.	13.3	13
706	Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. Heliyon, 2023, 9, e13853.	1.4	4
707	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. Archivum Immunologiae Et Therapiae Experimentalis, 2023, 71, .	1.0	4
708	Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro. Frontiers in Immunology, 0, 14, .	2.2	2
709	Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. Frontiers in Microbiology, 0, 14, .	1.5	5
710	Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections. Frontiers in Microbiology, 0, 13, .	1.5	1
711	A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. Archives of Virology, 2023, 168, .	0.9	3
712	In vitro immunogenic profile of recombinant SARS-CoV2 S1-RBD peptide in murine macrophage and microglial cells. Memorias Do Instituto Oswaldo Cruz, 0, 118, .	0.8	0
714	The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review. J, 2023, 6, 220-235.	0.6	3
722	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
730	T cell responses to SARS-COV-2. Progress in Molecular Biology and Translational Science, 2023, , .	0.9	0